Jin-huan Wei

No. 58, ZhongShan 2nd Road
Guangzhou, 510080, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 35 publications

TFE3-DualNet: An Interpretable Foundation Model-Based Deep Learning Ensemble for Diagnosing TFE3-Rearranged Renal Cell Carcinoma From Whole-Slide Images in a Two-Center Cohort.

TFE3-DualNet: An Interpretable Foundation Model-Based Deep Learning Ensemble for Diagnosing TFE3-Rearranged Renal Cell Carcinoma From Whole-Slide Images in a Two-Center Cohort.

Journal: Cancer medicine

Published: December 19, 2025

FKBP10 promotes M2 polarization of macrophage via MEK/ERK/CXCL8 axis and facilitates tumor progression in clear cell renal cell carcinoma.

FKBP10 promotes M2 polarization of macrophage via MEK/ERK/CXCL8 axis and facilitates tumor progression in clear cell renal cell carcinoma.

Journal: International journal of biological sciences

Published: May 14, 2025

Targeting the C/EBPβ-PRAME-EZH2 complex modulates the Netrin-4/AKT axis to inhibit renal cancer tumorigenesis and metastasis.

Targeting the C/EBPβ-PRAME-EZH2 complex modulates the Netrin-4/AKT axis to inhibit renal cancer tumorigenesis and metastasis.

Journal: Cell death and differentiation

Published: April 15, 2025

Misdiagnosis of hematuria after catheterization: A case report and literature review of posterior urethral hemangioma in a pediatric male.

Misdiagnosis of hematuria after catheterization: A case report and literature review of posterior urethral hemangioma in a pediatric male.

Journal: Urology case reports

Published: October 20, 2024

Transcriptomic profiling reveals mechanism, therapeutic potential, and prognostic value of cancer stemness characteristic in nasopharyngeal carcinoma.

Transcriptomic profiling reveals mechanism, therapeutic potential, and prognostic value of cancer stemness characteristic in nasopharyngeal carcinoma.

Journal: Functional & integrative genomics

Published: September 12, 2024

Development and validation of hierarchical signature for precision individualized therapy based on the landscape associated with necroptosis in clear cell renal cell carcinoma.

Development and validation of hierarchical signature for precision individualized therapy based on the landscape associated with necroptosis in clear cell renal cell carcinoma.

Journal: Frontiers in pharmacology

Published: July 25, 2024

Exploring the oncogenic potential of circSOD2 in clear cell renal cell carcinoma: a novel positive feedback loop.

Exploring the oncogenic potential of circSOD2 in clear cell renal cell carcinoma: a novel positive feedback loop.

Journal: Journal of translational medicine

Published: March 20, 2024

A multi-classifier system integrated by clinico-histology-genomic analysis for predicting recurrence of papillary renal cell carcinoma.

A multi-classifier system integrated by clinico-histology-genomic analysis for predicting recurrence of papillary renal cell carcinoma.

Journal: Nature communications

Published: December 18, 2023

Single-cell and spatial transcriptomics reveal 5-methylcytosine RNA methylation regulators immunologically reprograms tumor microenvironment characterizations, immunotherapy response and precision treatment of clear cell renal cell carcinoma.

Single-cell and spatial transcriptomics reveal 5-methylcytosine RNA methylation regulators immunologically reprograms tumor microenvironment characterizations, immunotherapy response and precision treatment of clear cell renal cell carcinoma.

Journal: Translational oncology

Published: April 20, 2023

Multimodal recurrence scoring system for prediction of clear cell renal cell carcinoma outcome: a discovery and validation study.

Multimodal recurrence scoring system for prediction of clear cell renal cell carcinoma outcome: a discovery and validation study.

Journal: The Lancet. Digital health

Published: December 21, 2022

A novel 7-chemokine-genes predictive signature for prognosis and therapeutic response in renal clear cell carcinoma.

A novel 7-chemokine-genes predictive signature for prognosis and therapeutic response in renal clear cell carcinoma.

Journal: Frontiers in pharmacology

Published: December 10, 2022

LZTFL1 inhibits kidney tumor cell growth by destabilizing AKT through ZNRF1-mediated ubiquitin proteosome pathway.

LZTFL1 inhibits kidney tumor cell growth by destabilizing AKT through ZNRF1-mediated ubiquitin proteosome pathway.

Journal: Oncogene

Published: September 30, 2022

Showing 1-12 of 35

Last Updated: 09/26/2026